Efficacy of Infliximab in Patients with Intestinal Behcet's Disease Refractory to Conventional Medication

被引:35
|
作者
Kinoshita, Hiroto [1 ]
Kunisaki, Reiko [1 ]
Yamamoto, Hisae [1 ]
Matsuda, Reikei [1 ]
Sasaki, Tomohiko [1 ]
Kimura, Hideaki [1 ]
Tanaka, Katsuaki [2 ]
Naganuma, Makoto [3 ]
Maeda, Shin [4 ]
机构
[1] Yokohama City Univ, Med Ctr, Ctr Inflammatory Bowel Dis, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan
[3] Keio Univ, Sch Med, Dept Internal Med, Tokyo 108, Japan
[4] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa, Japan
关键词
fulminant disease; infliximab; infusion interval; intestinal Behcet's disease; prednisolone; tumor necrosis factor-alpha; FACTOR-ALPHA ANTIBODY; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; THERAPY; METAANALYSIS; INVOLVEMENT;
D O I
10.2169/internalmedicine.52.0589
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the short-and long-term efficacy and safety of infliximab (IFX) in intestinal Behcet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.
引用
收藏
页码:1855 / 1862
页数:8
相关论文
共 50 条
  • [31] Efficacy and safety of systemic infliximab for uveitis in Behcet's disease
    Tobe, Aya
    Oshitari, Toshiyuki
    Yamamoto, Shuichi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [32] Effectiveness of infliximab in a patient with Behcet's disease refractory to immunosuppressive therapy
    Tacoronte, Angeles
    Gonzalez, Diana
    Sanchez, Miriam
    Moreno, Francisco
    Larrubia, Yolanda
    Villamanan, Elena
    Jimenez, Esperanza
    PHARMACY WORLD & SCIENCE, 2009, 31 (01): : 130 - 131
  • [33] SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY IN A COHORT OF PATIENTS WITH ESTABLISHED BEHCET'S DISEASE
    Venerito, V.
    Lopalco, G.
    Cantarini, L.
    Fabiani, C.
    Nivuori, M.
    Cacciapaglia, F.
    Galeazzi, M.
    Lapadula, G.
    Iannone, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1494 - 1495
  • [34] Serum concentrations of infliximab in patients with Behcet's disease
    Taguchi, C.
    Inoue, R.
    Yamakawa, R.
    ACTA OPHTHALMOLOGICA, 2013, 91
  • [35] Management of gastrointestinal Behcet's disease refractory to conventional treatment
    Hatemi, I.
    Hatemi, G.
    Erzin, Y.
    Celik, A. F.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S238 - S239
  • [36] INFLIXIMAB TREATMENT FOR UVEITIS IN PATIENTS WITH BEHCET'S DISEASE
    Uehara, Takeaki
    Takeno, Mitsuhiro
    Hama, Maasa
    Omura, Kenji
    Suda, Akiko
    Ihata, Atsushi
    Ueda, Atsuhisa
    Ishigatsubo, Yoshiaki
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S123 - S123
  • [37] Efficacy and tolerability of methotrexate therapy for refractory intestinal Behcet's disease: a single center experience
    Park, Jihye
    Cheon, Jae Hee
    Park, Yehyun
    Park, Soo Jung
    Kim, Tae Il
    Kim, Won Ho
    INTESTINAL RESEARCH, 2018, 16 (02) : 315 - 318
  • [38] Efficacy and tolerability of methotrexate therapy for refractory intestinal Behcet's disease: A single center experience
    Kim, W. H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S180 - S181
  • [39] Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behcet's disease
    Katsuyama, Atsuko
    Kusuhara, Sentaro
    Nishisho, Ryuto
    Matsumiya, Wataru
    Azumi, Atsushi
    Nakamura, Makoto
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 521 - 527
  • [40] Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab: rapid healing of Behcet's ulcer with infliximab
    Ju, Ji Hyeon
    Kwok, Seung-Ki
    Seo, Soo-Hong
    Yoon, Chong-Hyeon
    Kim, Ho-Youn
    Park, Sung-Hwan
    CLINICAL RHEUMATOLOGY, 2007, 26 (08) : 1383 - 1385